Anja Pohl-Schickinger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anja Pohl-Schickinger has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Brigitte Stiller
Department of Congenital Heart Disease, Campus Virchow Klinikum, Berlin, Germany
2 shared publications- Felix Berger
Department of Congenital Heart Disease—Pediatric Cardiology, Deutsches Herzzentrum der Charité, Augustenburger Platz 1, 13353 Berlin, Germany
2 shared publications Matthias Redlin
Department of Anesthesia, Deutsches Herzzentrum Berlin, Campus Virchow Klinikum, Berlin, Germany
2 shared publicationsMichael Hübler
Department of Cardiothoracic and Vascular Surgery, Campus Virchow Klinikum, Berlin, Germany
2 shared publicationsC. Bassir
Department of Pediatric Radiology, Campus Virchow Klinikum, University Hospital Charité, Berlin, Germany
1 shared publicationD. Hüseman
Department of Neonatology, Campus Virchow Klinikum, University Hospital Charité, Berlin, Germany
1 shared publication
Latest Publications
- 17 May 2010
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 20 (5) , 505-508
Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease
Patients with cyanotic congenital cardiac disease often develop major aortopulmonary collaterals. Vascular endothelial growth factor is a key promoter of angiogenesis. Its soluble receptor-1 acts as a potent antagonist. We studied 30 infants with cyanotic congenital cardiac disease and 27 infants with acyanotic congenital cardiac disease. Central venous plasma vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 levels were measured before, and 24 and 96 hours after surgery. There was no difference between plasma vascular endothelial growth factor levels in infants with cyanotic and those with acyanotic congenital cardiac disease. In cyanotic infants, the soluble vascular endothelial growth factor receptor-1 levels tended to be higher than in the acyanotic infants. In conclusion, there is no significant difference in the plasma levels of vascular endothelial growth factor and its soluble receptor-1 between infants with cyanotic and those with acyanotic congenital cardiac disease.
- 17 May 2010
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 20 (5) , 505-508
Vascular endothelial growth factor and its soluble receptor in infants with congenital cardiac disease
Patients with cyanotic congenital cardiac disease often develop major aortopulmonary collaterals. Vascular endothelial growth factor is a key promoter of angiogenesis. Its soluble receptor-1 acts as a potent antagonist. We studied 30 infants with cyanotic congenital cardiac disease and 27 infants with acyanotic congenital cardiac disease. Central venous plasma vascular endothelial growth factor and soluble vascular endothelial growth factor receptor-1 levels were measured before, and 24 and 96 hours after surgery. There was no difference between plasma vascular endothelial growth factor levels in infants with cyanotic and those with acyanotic congenital cardiac disease. In cyanotic infants, the soluble vascular endothelial growth factor receptor-1 levels tended to be higher than in the acyanotic infants. In conclusion, there is no significant difference in the plasma levels of vascular endothelial growth factor and its soluble receptor-1 between infants with cyanotic and those with acyanotic congenital cardiac disease.
- 22 January 2008
- Published by Wiley in Pediatric Anesthesia
- Vol. 18 (3) , 217-222
Intravenous clonidine infusion in infants after cardiovascular surgery
Summary: Background: The aim of this study was to investigate the hemodynamic profile and heart rhythm in infants who were given intravenous clonidine infusion after prolonged analgesia/sedation following cardiac surgery.Methods: This is a single center retrospective review. A total of 542 cardiovascular surgical procedures in infants aged 0–24 months with congenital heart disease were performed between 01/2003 and 12/2005 at the Deutsches Herzzentrum in Berlin. The majority received no long‐term analgesia/sedation, but 50 (9%) of these infants received clonidine (dosed at 0.18–3.6 μg·kg−1·h−1) for sedation and to reduce withdrawal symptoms such as CNS hyperactivation, hypertension, tachycardia, and fever. The hospital records of these infants were studied.Results: Fifty infants (median age 5.0 months, median body weight 5.3 kg, 32 males/18 females) received prolonged analgesia/sedation to ensure hemodynamic stability. Clonidine infusion started on day 5 (median) after surgery. During clonidine treatment we found an age‐related normalized profile of hemodynamic parameters with a reduction of heart rate and mean arterial pressure from the upper norm to the mean within 24 h (P < 0.001). In no case did clonidine cause low blood pressure resulting in additional therapy to reach the target blood pressure. There were no adverse effects on cardiac rhythm, especially no onset of atrioventricular block. Midazolam, fentanyl, and other opioids could be ended on day 4 of clonidine treatment.Conclusions: Although off‐label, it is feasible to use clonidine infusions in infants in the PICU setting after cardiac surgery without hemodynamic problems arising.
- 22 January 2008
- Published by Wiley in Pediatric Anesthesia
- Vol. 18 (3) , 217-222
Intravenous clonidine infusion in infants after cardiovascular surgery
Summary: Background: The aim of this study was to investigate the hemodynamic profile and heart rhythm in infants who were given intravenous clonidine infusion after prolonged analgesia/sedation following cardiac surgery.Methods: This is a single center retrospective review. A total of 542 cardiovascular surgical procedures in infants aged 0–24 months with congenital heart disease were performed between 01/2003 and 12/2005 at the Deutsches Herzzentrum in Berlin. The majority received no long‐term analgesia/sedation, but 50 (9%) of these infants received clonidine (dosed at 0.18–3.6 μg·kg−1·h−1) for sedation and to reduce withdrawal symptoms such as CNS hyperactivation, hypertension, tachycardia, and fever. The hospital records of these infants were studied.Results: Fifty infants (median age 5.0 months, median body weight 5.3 kg, 32 males/18 females) received prolonged analgesia/sedation to ensure hemodynamic stability. Clonidine infusion started on day 5 (median) after surgery. During clonidine treatment we found an age‐related normalized profile of hemodynamic parameters with a reduction of heart rate and mean arterial pressure from the upper norm to the mean within 24 h (P < 0.001). In no case did clonidine cause low blood pressure resulting in additional therapy to reach the target blood pressure. There were no adverse effects on cardiac rhythm, especially no onset of atrioventricular block. Midazolam, fentanyl, and other opioids could be ended on day 4 of clonidine treatment.Conclusions: Although off‐label, it is feasible to use clonidine infusions in infants in the PICU setting after cardiac surgery without hemodynamic problems arising.
- Open Access
- 3 August 2006
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 28 (3) , 341-344
Echogenic foci in the dilated fetal colon may be associated with the presence of a rectourinary fistula
Intraintestinal meconium calcification in the fetus and newborn is a rare finding, occurring in patients with intestinal obstruction. The intraluminal location of the enterolithiasis enables differentiation from calcifications that are secondary to bowel perforation and meconium peritonitis. We report on a term male neonate with VACTERL (vertebral defects, imperforate anus, cardiac anomalies, tracheoesophageal fistula, renal anomalies, limb anomalies) association and rectourethral fistula, in whom enterolithiasis was documented by prenatal ultrasound imaging at 21 weeks' gestation. A review of the literature and a summary of all previously described cases of neonates with intraluminal meconium calcifications are provided. Prenatal ultrasonographic detection of enterolithiasis in fetuses with anal atresia may indicate the presence of an enterourinary fistula. Copyright © 2006 ISUOG. Published by John Wiley & Sons, Ltd.
- 3 August 2006
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 28 (3) , 341-344
Open AccessEchogenic foci in the dilated fetal colon may be associated with the presence of a rectourinary fistula
Intraintestinal meconium calcification in the fetus and newborn is a rare finding, occurring in patients with intestinal obstruction. The intraluminal location of the enterolithiasis enables differentiation from calcifications that are secondary to bowel perforation and meconium peritonitis. We report on a term male neonate with VACTERL (vertebral defects, imperforate anus, cardiac anomalies, tracheoesophageal fistula, renal anomalies, limb anomalies) association and rectourethral fistula, in whom enterolithiasis was documented by prenatal ultrasound imaging at 21 weeks' gestation. A review of the literature and a summary of all previously described cases of neonates with intraluminal meconium calcifications are provided. Prenatal ultrasonographic detection of enterolithiasis in fetuses with anal atresia may indicate the presence of an enterourinary fistula. Copyright © 2006 ISUOG. Published by John Wiley & Sons, Ltd.